Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology

Journal of Diabetes

Volumn 5, Issue 4, 2013, Pages 406-415

  Gao, Xin ^a   Fan, Jian Gao ^b  

^a FUDAN UNIVERSITY   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Diagnosis; Management; Metabolic disorders; NAFLD

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; FERRITIN; HEPATITIS B SURFACE ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; METFORMIN; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE; PIOGLITAZONE; POLYPHENOL; TETRAHYDROLIPSTATIN; TRANSFERRIN; URSODEOXYCHOLIC ACID;

ALCOHOL CONSUMPTION; BARIATRIC SURGERY; CARDIOVASCULAR MORTALITY; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DIETARY INTAKE; DYSLIPIDEMIA; DYSPEPSIA; ECHOGRAPHY; EDEMA; FATIGUE; FATTY LIVER; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEPATOSPLENOMEGALY; HUMAN; HYPERTRANSAMINASEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PAIN; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RISK FACTOR; SCREENING TEST; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

DIAGNOSIS; MANAGEMENT; METABOLIC DISORDERS; NAFLD;

CHINA; CONSENSUS; ENDOCRINOLOGY; FATTY LIVER; HUMANS; LIVER; METABOLIC DISEASES; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84887014853     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12056     Document Type: Review

References (61)

1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006; 43 (Suppl 1): S99-112.
2. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol. 2008; 48 (Suppl 1): S104-112.
3. Angulo P. GI epidemiology: Nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007; 25: 883-889.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1222-1231.
5. Wong VW. Nonalcoholic fatty liver disease in Asia: A story of growth. J Gastroenterol Hepatol. 2013; 28: 18-23.
6. Fan JG, Zhu J, Li XJ etal. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005; 20: 1825-1832.
7. Wong VW, Chu WC, Wong GL etal. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012; 61: 409-415.
8. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A, Asia-Pacific Working Party for NAFLD. What are the risk factors and settings of non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol. 2007; 22: 794-800.
9. Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012; 27: 420-428.
10. Ortiz-Lopez C, Lomonaco R, Orsak B etal. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012; 35: 873-887.
11. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-285.
12. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: Selected practical issues in their management. Hepatology. 2009; 49: 306-317.
13. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007; 30: 2940-2944.
14. Park SK, Seo MH, Shin HC, Ryoo JH. The clinical availability of non-alcoholic fatty liver disease as an early predictor of type2 diabetes mellitus in Korean men: 5-years' prospective cohort study. Diabetes Care. 2005; 28: 1757-1762.
15. Adams LA, Waters OR, Knuiman MW etal. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An eleven-year follow-up study. Am J Gastroenterol. 2009; 104: 861-867.
16. Kang H, Greenson JK, Omo JT etal. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol. 2006; 101: 2247-2253.
17. Ryan MC, Wilson AM, Slavin J etal. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2005; 28: 1222-1224.
18. Leite NC, Villela-Nogueira CA, Pannain VL etal. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: Prevalences and correlated factors. Liver Int. 2011; 31: 700-706.
19. American Gastroenterological Association. American Gastroenterological Association medical position statement: Nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 1702-1704.
20. Farrell GC, Chitturi S, Lau GK etal. Guidelines for the assessment and mangement of non-alcoholic fatty liver disease in the Asia-Pacific region. Executive summary. J Gastroenterol Hepatol. 2007; 22: 775-777.
21. Kowdley KV. The role of iron in nonalcoholic fatty liver disease: The story continues. Gastroenterology. 2010; 138: 817-819.
22. Lin TJ, Lin CL, Wang CS, Liu SO, Liao LY. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan. World J Gastroenterol. 2005; 11: 3905-3908.
23. Vuppalanchi R, Gould RJ, Wilson LA etal. Clinical significance of serum autoantibodies in patients with NAFLD: Results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2012; 6: 379-385.
24. Yang Z, Liang Y, Qin B, Li C, Zhong R. Clinical significance of conventional serum autoantibodies for various liver diseases in a Chinese population. Clin Biochem. 2012; 45: 203-206.
25. McAvoy N, Lockman A, Hayes PC. Non-alcoholic fatty liver disease (NAFLD): An overview. J R Coll Physicians Edinb. 2007; 37: 9-17.
26. Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease(NAFLD). Ann Med. 2009; 41: 265-278.
27. Dasarathy S, Dasarathy J, Khiyami A etal. Validity of real time ultrasound in the diagnosis of hepatic steatosis; A prospective study. J Hepatol. 2009; 51: 1061-1067.
28. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007; 189: W320-323.
29. Mazhar SM, Shiehmorteza M, Sorlin CB. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol. 2009; 7: 135-140.
30. Zeng MD, Fan JG, Lu LG etal. Chinese National Concensus Workshop on Nonalcoholic Fatty Liver Disease. Guildelines for the diagnosis and treatment of nonalcoholic fatty liver disease. J Dig Dis. 2008; 9: 108-112.
31. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51: 433-445.
32. Szczepaniak LS, Nurenberg P, Leonard D etal. Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288: E462-E468.
33. Xia MF, Yan HM, He WY etal. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: An improvement method. Obesity. 2012; 20: 444-452.
34. Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011; 43: 617-649.
35. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55: 2005-2023.
36. Wong VW, Wong GL, Chim AM etal. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008; 103: 1682-1688.
37. Xun YH, Fan JG, Zang GQ etal. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease. J Dig Dis. 2012; 13: 588-595.
38. Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. Chin J Hepatol. 2006; 14: 161-163. (in Chinese).
39. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321.
40. Liu M, Yan HM, Gao X etal. Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease. Zhonghua Yi Xue Za Zhi. 2007; 87: 253-255. (in Chinese).
41. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005; 129: 113-121.
42. Ekstedt M, Franzén LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865-873.
43. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36 (Suppl 1): S11-66.
44. International Diabetes Federation. Criteria for metabolic syndrome. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf (accessed 27 April 2013).
45. Greenland P, Alpert JS, Beller GA etal. ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010; 56: e50-103.
46. Hurst RT, Ng DW, Kendall C, Khandheria B. Clinical use of carotid intima-media thickness: Review of the literature. J Am Soc Echocardiogr. 2007; 20: 907-914.
47. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol. 2008; 49: 600-607.
48. Fan JG, Jia JD, Li YM etal. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. J Dig Dis. 2011; 12: 38-44.
49. Promrat K, Kleiner DE, Niemeier HM etal. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51: 121-129.
50. Cortez-Pinto H, Machado M. Impact of body weight, diet and lifestyle on non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2008; 2: 217-231.
51. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care. 2008; 31 (Suppl 2): S269-277.
52. Zelber-Sagi S, Kessler A, Brazowsky E etal. A doubleblind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006; 4: 639-644.
53. Harrison SA, Brunt EM, Fecht WJ, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): A randomized prospective trial. Hepatology. 2009; 49: 80-86.
54. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003; 38: 1008-1017.
55. Ratziu V, Giral P, Jacqueminet S etal. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135: 100-110.
56. Aithal GP, Thomas JA, Kaye PV etal. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135: 1176-1184.
57. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685.
58. Lincoff A, Wolski K, Nicholls S, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA. 2007; 298: 1180-1188.
59. Grattagliano I, Portincasa P, Palmieri VO etal. Managing novadcoholic fatty liver disease: Recommendations for family physicians. Can Fam Physician. 2007; 53: 857-863.
60. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008; 134: 1682-1698.
61. Guyatt GH, Oxman AD, Vist GE etal. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924-926.